Document is current
Any future updates will be listed below
-
Authors
Sethuram, S. https://orcid.org/0000-0002-7101-5045
Levy, T. https://orcid.org/0000-0003-2207-0440
Foss-Feig, J. https://orcid.org/0000-0002-1491-8248
Halpern, D. https://orcid.org/0000-0001-6745-1197
Sandin, S. https://orcid.org/0000-0001-6994-4884
Siper, P. M. https://orcid.org/0000-0002-9659-8232
Walker, H.
Buxbaum, J. D. https://orcid.org/0000-0001-8898-8313
Rapaport, R. https://orcid.org/0000-0002-0915-3551
Kolevzon, A. https://orcid.org/0000-0001-8129-2671
-
Funding
Funding for this research was provided by:
Beatrice and Samuel A. Seaver Foundation
New York Community Trust Foundation
- License Information
-
More Information
Article History
Received: 22 September 2021
Accepted: 17 January 2022
First Online: 29 January 2022
Declarations
:
: The protocol was approved by the Mount Sinai Program for the Protection of Human Subjects, and all caregivers signed informed consent.
: Not applicable.
: AK receives research support from AMO Pharma and consults to Acadia, Alkermes, Jaguar, Neuren, GW Pharma, and Ovid Therapeutics. JDB has a shared patent with Mount Sinai for IGF-1 in Phelan–McDermid syndrome. No other authors have competing interests to disclose.
